Natera, Inc. reported its financial results for the third quarter ended September 30, 2024, with total revenues reaching $439.8 million. This represents a substantial 64% increase compared to the third quarter of 2023, demonstrating robust top-line growth for the company.
Despite the strong revenue performance, Natera reported a net loss of $31.6 million for the quarter. This translates to a loss of $0.26 per diluted share, reflecting ongoing investments in research and development and commercial expansion.
The significant revenue growth indicates increasing adoption and demand for Natera's cell-free DNA and genetic testing products. This financial update provides investors with key insights into the company's operational execution and market penetration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.